Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal dosing of first- and second-generation cephalosporins in obese surgical patients
2011-004070-29Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Sep 2011
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefuroxime and cefazolin (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Optimal dosing of first- and second-generation cephalosporins in obese patients. Started Sep 2011; status: completed.
02
Drugs
cefuroximecefazolin
Beyond the preview
Go deeper on 2011-004070-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004070-29.